Medosome Biotec LLC

Medosome Biotec LLC, a for-profit limited liability partnership based in Bloomington, Indiana, develops genetically engineered probiotics and metabolic therapeutics for federal biomedical research funding as a prime recipient of federal grants from the National Institutes of Health. The company operates exclusively as a grant recipient (100% of awards) with no contract prime footprint and competes in full-and-open federal research grant competitions; it maintains a subsidiary, Nuteric Natural Health Products LLC, also structured as an LLC.

Medosome's capability portfolio centers on two distinct therapeutic platforms. The first is engineered probiotic delivery systems: the company has developed Lactobacillus-based live vectors capable of oral delivery of peptide and protein therapeutics, with built-in biocontainment mechanisms. Representative work includes a $356,251 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant awarded July 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), focused on genetically engineered probiotics producing and delivering glucagon-like peptide-1 (GLP-1) for type 2 diabetes and obesity treatment. An earlier August 1, 2023 National Center for Advancing Translational Sciences (NCATS) grant funded development of next-generation probiotics platforms with antibiotic-resistance-gene-free expression systems and inducible kill-switches for biocontainment—work running through July 31, 2025. The second platform targets metabolic and immune dysfunction in sepsis: a September 12, 2024 National Institute of General Medical Sciences (NIGMS) Small Business Technology Transfer Phase I/Phase II Fast-Track grant funds evaluation of dichloroacetate (DCA), a pyruvate dehydrogenase kinase inhibitor, as a therapy to restore mitochondrial bioenergetic function in septic shock, in collaboration with the University of Florida, Wake Forest University, and Northwestern University; that award runs through September 11, 2025.

Customer concentration is sharp and sustained across NIH institutes. The top five customer entities (all within HHS/NIH) account for 81% of awards by count: the National Institute of Diabetes and Digestive and Kidney Diseases (4 awards), the broader NIH (3 awards), the National Institute of Child Health and Human Development (3 awards), the National Institute of Allergy and Infectious Diseases (2 awards), and HHS at large (1 award). Total obligated dollars across all sixteen awards since 2015 stand at $21.4 million. Activity has been episodic—two awards in 2018, three in 2019, then a gap to one award each in 2023 and 2024, with the most recent award in July 2026—and only one award (the NIGMS sepsis-therapy grant) reaches ultimate completion within the next twenty-four months, presenting limited near-term recompete exposure.